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Colorectal cancer (CRC) risk is modulated by diet and there is convincing evidence of reduced
risk with higher non-digestible carbohydrates (NDCs) consumption. Resistant starch (RS), a
NDC, positively modulates the expression of oncogenic microRNAs, suggesting that this could
be a mechanism through which NDCs protect against CRC. The present study aimed to
investigate the effects of supplementation with two NDCs, RS, and polydextrose (PD), on
microRNA expression in the macroscopically-normal human rectal epithelium using samples
from the DISC Study, a randomized, double-blind, placebo-controlled dietary intervention. We
screened 1008 miRNAs in pooled post-intervention rectal mucosal samples from participants
allocated to the double placebo group and those supplemented with both RS and PD. A total of
111 miRNAs were up- or down-regulated by at least twofold in the RS + PD group compared
with the control group. From these, eight were selected for quantification in individual
participant samples by qPCR, and fold-change directionwas consistent with the array for seven
miRNAs. The inconsistency for miR-133b and the lower fold-change values observed for the
seven miRNAs is probably because qPCR of individual participant samples is a more robust and
sensitive method of quantification than the array. miR-32 expression was increased by
approximately threefold (P = 0.033) in the rectal mucosa of participants supplemented with
RS + PD compared with placebo. miR-32 is involved in the regulation of processes such as cell
proliferation that are dysregulated in CRC. Furthermore, miR-32 may affect non-canonical
NF-κB signaling via regulation of TRAF3 expression and consequently NIK stabilization.
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1 | INTRODUCTION
Colorectal cancer (CRC) is the third most common cancer worldwide
and fourth most common cause of cancer-related death.1 CRC risk is
significantly modulated by lifestyle factors including diet. The World
Cancer Research Fund/American Institute for Cancer report con-
cluded that there is convincing evidence for lower CRC riskwith higher
consumption of dietary fibre.2 This includes non-digestible carbohy-
drates (NDCs), such as resistant starch (RS) and polydextrose (PD), that
resist digestion in the small intestine and are fermented by bacteria in
Abbreviations: CRC, colorectal cancer; HDAC, histone deacetylase; miRNA, microRNA; NDC, non-digestible carbohydrates; PD, polydextrose; RS, resistant starch;
SCFA, short chain fatty acid.
Trial registration: The DISC Study is registered with ClinicalTrials.gov (NCT01214681).
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
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the large bowel to produce the short-chain fatty acids (SCFAs)
butyrate (the preferred energy source for colonocytes), propionate
and acetate.
Butyrate, produced primarily by bacterial species of the
Clostridia, Roseburia, and Eubacteria genera,3 has chemoprotective
anti-inflammatory and anti-proliferative properties and regulates
apoptosis in both normal and cancerous cells.4,5 Butyrate has effects
on epigenetic mechanisms that regulate gene expression and are
important in colorectal tumorigenesis, including its role as a histone
deacetylase inhibitor (HDACi)6 and effects on microRNA (miRNA)
expression.7,8
miRNAs are small, non-coding RNAs that regulate the expression
of their target genes at a post-transcriptional level by degrading
messenger RNA or blocking translation. Over 1500miRNAs have been
identified in humans and have been predicted to regulate the
expression of up to 60%of genes,9,10 consequently regulatingmultiple
biological processes including cell proliferation, differentiation, and
apoptosis. Abnormal miRNA expression is observed in colorectal
tissue as well as plasma, urine, and stool samples from CRC
patients.11,12
miRNA expression is modulated by multiple dietary factors; for
example the expression of 250, 198, and 99 miRNAs was associated
with intakes of carbohydrate, sucrose, and wholegrains, respectively,
and some of these miRNAs showed differential expression between
normal and tumor tissue.13 A limited number of studies have
investigated the effects of NDCs and butyrate on miRNA expression
in the cells from the large bowel epithelium, and the majority of
studies investigating the role of miRNAs in colorectal carcinogenesis
have been performed in CRC cell lines or using tissue from resected
tumors. Using a microarray-based approach, Humphreys and
colleagues observed that treatment of HT-29 colorectal adenocar-
cinoma cells with 5 mM butyrate for 48 h altered the expression 69
miRNAs.14 Follow-up analysis by qPCR showed that butyrate
treatment reduced expression of miRNAs belonging to the
oncogenic miR-17-92 cluster and decreased cell proliferation. Hu
et al also reported that butyrate exposure altered expression of 44
miRNAs in HCT-116 cells, 18 of which were confirmed by qPCR.7
Humphreys et al were the first to investigate the effects of RS and
butyrate on expression of miR-17-92 cluster members in a human
intervention study.15 Supplementation of a high red meat diet, which
increased miR-17-92 expression by approximately 30%, with
butyrylated RS for 4 wk restored expression to baseline levels,
suggesting that RS reversed the detrimental effects of red meat on
expression of oncogenic miRNAs.
In the current study, we hypothesised that NDCs are
protective against CRC by regulating the expression of miRNAs,
in particular by down-regulating expression of miRNAs that are
upregulated in CRC. For the first time, we used a whole miRNome
PCR array to screen for candidate miRNAs that are differentially
expressed in the macroscopically-normal rectal mucosa of healthy
participants following supplementation with two NDCs (RS and
PD). We validated the findings from the miRNome array for eight
miRNAs by qPCR using RNA samples from 29 individual
participants.
2 | METHODS
2.1 | Study participants
Participants were recruited from gastroenterology out-patients
departments at North Tyneside General Hospital, North Shields,
UK and Wansbeck General Hospital, Ashington, UK between May
2010 and July 2011. The exclusion criteria included being aged
<16 or >85 years, being a prisoner at the time of endoscopy, being
pregnant, or planning to become pregnant, diabetes mellitus,
familial adenomatous polyposis syndrome, Lynch Syndrome,
known colorectal tumor or prior colorectal cancer, prior colorectal
resection, active colonic inflammation at endoscopy, iatrogenic
perforation at endoscopy, incomplete left-sided examination,
colorectal carcinoma discovered at endoscopy, CRC on histology,
chemotherapy in the last 6 months, administering non-steroidal
anti-inflammatories, anti-coagulants, or immunosuppressive
medication.
2.2 | Intervention methodology
The samples utilized for the present studywere collected as part of the
DISC Study, a double-blind, randomized, placebo-controlled dietary
intervention that supplemented healthy participants with RS and/or
PD for 50 d in a 2 × 2 factorial design.16 For the purpose of this study,
the following two groups of participants were used:
 Double placebo (Control): 12 g of Maltodextrin and 23 g of Amioca
starch.
 Double intervention (RS + PD): 23 g of Hi-maize® 260 and 12 g of
Litesse® Ultra™. For the purposes of this paper, this group is
described as the Intervention group.
Anthropometric measurements were taken at baseline and post-
intervention. Participants also completed a food frequency question-
naire and a lifestyle questionnaire that collected information on
physical activity and smoking status.
2.3 | Human colorectal tissue samples
This study was approved by the Newcastle and North Tyneside
Research Ethics Committee (REC No. 09/H0907/77). Mucosal
biopsies from the rectum (10 cm from the ano-rectal verge) were
collected pre-intervention at endoscopy (colonoscopy or flexible
sigmoidoscopy) and post-intervention at rigid sigmoidoscopy.
2.4 | Study design
We designed a two-phase study to identify miRNAs modulated by
NDCs (see Fig. 1). In the screening phase, we pooled equivalent
amounts of cDNA reverse-transcribed from RNA extracted from
the rectal mucosa of each of 15 Control participants (supple-
mented with double placebo) and of 14 Intervention participants
(supplemented with RS and PD). Abundance of 1008 miRNAs was
quantified in each pooled sample by qPCR using the Human
2 | MALCOMSON ET AL.
miRNome miScript® miRNA PCR array (Qiagen). A total of 111
miRNAs were up- or down-regulated by more than twofold in the
Intervention compared with the Control sample. This number was
reduced to 29 miRNAs by excluding those which did not have a Ct
value of <30 in at least one of the samples. From these, a total of
seven miRNAs were selected to be validated by qPCR in the
individual pre- and post-intervention rectal mucosa samples. In
addition, miR-32 was selected for quantification by qPCR due to its
role in colorectal carcinogenesis.17
2.5 | Isolation of total RNA
Total RNA was extracted from half a rectal mucosal biopsy using
the miRNeasy Mini Kit (Qiagen, UK) following the manufacturer’s
instructions. Tissue disruption was performed by shaking the
tissues with five 3 mm glass beads (VWR, UK) for 1 m in QIAzol
Lysis Reagent (miRNeasy Mini Kit) using an amalgamator. The
lysate and beads were transferred to QiaShredders (Qiagen, UK)
for homogenization by centrifugation for 2 m at maximum speed.
RNA was eluted in 30 µL of RNase-free water. Concentration and
RNA purity were determined using the NanoDrop 1000
spectrophotometer (Thermo Scientific) and NanoDrop 1000
Software version 3.7.1. RNA integrity was assessed by agarose
gel electrophoresis.
2.6 | Synthesis of cDNA
cDNAwas synthesized from 0.8 μg of RNA using the miScript II RT Kit
(Qiagen) as described by themanufacturer. ThemiScriptHiSpecBuffer
(5×) was used during reverse transcription to enable subsequent
quantification of mature miRNAs. The samples were incubated for
60m at 37°C followed by 5m at 95°C using the Sensoquest lab cycler
(Göttingen, Germany).
2.7 | miRNome array
Prior to analyses, cDNA samples were diluted ten times. Expression of
1008 miRNAs plus six quality controls and six reference RNAs were
quantified by qPCR using the 96 well plate Human miRNome
miScript® miRNA PCR array (Qiagen) as described by the manufac-
turer (see Fig. 1). miRNAs with Ct values over 35 were classed as
undetected. Raw data were normalized against the six reference RNAs
and, as subsequent validation of miRNA expression by qPCR was
normalized against only two reference RNAs, also against the selected
two reference RNAs (RNU-6 and SNORD68) to check that these data
were comparable with both normalization methods. Technical
performance of the plates was checked using the integrated quality
controls included on all the array plates.
2.8 | Validation of miRNA expression by quantitative
PCR
Quantification of the eight selected miRNAs for validation and two
reference RNAs (SNORD68 and RNU-6) in individual samples was
performed by qPCR using the Applied Biosystems® StepOnePlus™
system, the miScript SYBR Green PCR Kit and custom miScript primer
assays (Qiagen, UK) as described by the manufacturer.
Prior to analysis of the qPCR data, the melt curves were checked
for a single peak and a constant threshold value was set for each
miRNA separately for all of the samples by taking the average of the
set thresholds for each miRNA for every plate. Ct values greater than
35 were classed as undetected and raw data were normalized relative
to the geometric mean of RNU-6 and SNORD68.
2.9 | Statistical analyses
The data, expressed as adjusted relative copies (2−ΔCt × 1000, relative
to the geometric mean of SNORD68 and RNU-6), were analyzed using
Minitab® v.17. Prior to analyses, data were checked for a normal
distribution using the Kolmogorov-Smirnov test. Data that were not
normally-distributed were transformed appropriately, using log10 or
by taking the square root.
Differences between the two treatment groups were analyzed
using the ANOVA General Linear Model (GLM), adjusting for pre-
intervention expression, age, gender, endoscopy procedure, smoking
status, and BMI as covariates.
FIGURE 1 Flow-chart showing the study design and selection of
miRNAs for quantification in individual samples by qPCR. From
1008 miRNAs quantified, 111 miRNAs showed a difference in
expression between pooled control and intervention samples. From
these, eight miRNAs were selected for quantification in individual
participant samples
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3 | RESULTS
3.1 | Participant characteristics
Samples from a total of 29 participants were utilized for this study,
comprising 15 Control participants and 14 Double Intervention
participants. Participant characteristics are summarized in Table 1.
Mean age of participants in both groups was similar (49 and 51
years for Control and RS + PD, respectively), with the youngest
participant being aged 30 and oldest aged 74. With the exception of
one Control participant, all participants were Caucasian. In both
groups, colonoscopy was the main endoscopy procedure at baseline.
The participantswerewell-matched for BMI (mostwere overweight or
obese) and smoking behavior (73% and 71% were never or former
smokers for Control and RS + PD groups, respectively). The observed
similarity in participant characteristics is evidence of the success of the
randomization process.
3.2 | Human miRNome miScript miRNA PCR array
The expression of 1008 miRNAs was quantified in pooled post-
intervention samples from participants in the Control and from the
RS + PD group using Qiagen’s Human miRNome array. All of the array
plates passed the quality control checks. A total of 217 miRNAs (Ct
values ≥35), equating to 22% of the 1008 quantified miRNAs, were
undetected in one or both of the Control and RS + PD samples. The
proportions of miRNAs in each Ct value range were comparable for
both the Control and Intervention samples (Fig. 2A).
A cut-off value of twofold difference (up- or down-regulated) in
expression, relative to all six reference RNAs, for themiRNAs between
the RS + PD group and the Control group was used as an index of
potentially differentially-expressed miRNAs. A total of 33 miRNAs
were up-regulated ≥2-fold and 78 miRNAs were down-regulated
≥2-fold in the Intervention compared with Control sample
(Additional File 2).
3.3 | Normalization of PCR array data
Raw data were normalized relative to all six reference RNAs included
on the array plates and to the two selected reference RNAs (RNU-6
and SNORD68) used during the validation stage of the study. We
checked that both normalization methods were comparable for all
111 miRNAs showing a fold-change ≥ 2 (Fig. 2B). From the 1008
miRNAs for which there were probes on the array, 69 miRNAs
showed ≥2-fold difference in expression when normalized relative
to only RNU-6 and SNORD-68 compared with 111 for normalization
to all six reference RNAs. In all cases where the normalization
methods resulted in different fold-change results, fold-changes were
very small (between −1.13 and 1.12) and the difference in fold-
change between the two normalization methods did not exceed
0.14.
3.4 | Selection of miRNAs for individual participant
analysis
From the analysis of the 1008 miRNAs, two lists were compiled
comprising miRNAs with ≥2-fold up- or down-regulation, which
included a total of 111 miRNAs. Each list was then analyzed
individually and those with a comment of “OKAY” or “A” on the
miScript miRNA PCR Array Data Analysis Web Portal output were
selected; this reduced the number of miRNAs to six up-regulated
≥2-fold and 23 down-regulated ≥2-fold. The miScript miRNA PCR
Array Data Analysis Web Portal defined a comment of “OKAY” as a
miRNA with reasonably low Ct values (<30) in both samples and
comment of “A” as a miRNA with a relatively high (>30) Ct value in
either the control or test sample and a reasonably low Ct value
(<30) in the other sample. Because of inadequate melt curves,
miR-3156-5p, miR-637, and miR-600 were excluded at this stage,
leaving five miRNAs up-regulated ≥2-fold (Fig. 2C) and 21 down-
regulated ≥2-fold (Fig. 2D).
From the remaining 26 miRNAs, the top three miRNAs showing
the greatest fold up-regulation and the top four miRNAs showing the
greatest fold down-regulation were selected for further investigation.
These were: miR-135a-5p, miR-517-5p, and miR-26a-1-3p (upregu-
lated genes) and miR-133b, miR-640, miR-1287-5p, and miR-127-3p
(down-regulated genes). In addition, miR-32 was selected due to its
role in colorectal carcinogenesis.17
3.5 | Quantification of miRNA expression in
individual participants by qPCR
qPCR was run using samples from each individual participant in the
Control group (n = 15) and in the RS + PD group (n = 14) for the
TABLE 1 Participant characteristics for vontrol and RS + PD groups
Variable Control RS + PD P-value
N 15 14
Age
Mean (years) 49.2 51.1 0.669
Range (years) 30-70 36-74
Gender
Female (%) 7 (47) 3 (21) 0.256
Male (%) 8 (53) 11 (79)
Ethnicity
Caucasian (%) 14 (93) 14 (100)
Black african (%) 1 (7) 0 (0)
Endoscopy procedure
Colonoscopy (%) 3 (20) 3 (21) 0.924
Flexible sigmoidoscopy (%) 12 (80) 11 (79)
BMI
Mean (kg/m2) 29.7 29.7 0.971
Range (kg/m2) 23.5-37.0 23.5-40.0
Smoking status
Never (%) 7 (46.6) 4 (28.6) 0.553
Former (%) 4 (26.7) 6 (42.8)
Current (%) 4 (26.7) 4 (28.6)
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eight selected miRNAs. Differences in post-intervention miRNA
expression were analyzed using the ANOVA GLM. Post-
intervention expression of miR-32 was approximately threefold
greater in participants given RS and PD compared with the Control
group (P = 0.033) (Table 2). There were no statistically significant
differences in the expression of miR-26a, miR-127, miR-133b,
miR-135a, miR-517, miR-640, or miR-1287 between the Control
and RS + PD groups.
3.6 | Comparison of PCR array and qPCR of
individual participant data
Quantification of the eight selected miRNAs in individual samples
allowed for comparison with the originally obtained PCR array data.
For the PCR array data, fold-change was calculated for eachmiRNA by
dividing the relative copies (2−ΔCt) for the pooled RS + PD group
sample by that for the pooled Control group sample. For the individual
FIGURE 2 Whole miRNome PCR array (A) proportion of miRNAs with Ct values in different ranges, (B) correlation of data presented as
fold-change normalised relative to RNU-6 and SNORD-68 versus all six reference miRNAs, and miRNAs showing (C) ≥2-fold up-regulation and
(D) ≥2-fold down-regulation in the RS + PD group compared with the Control group
TABLE 2 Post-intervention differences in miRNA expression in DISC Study participants allocated to the control group and to the RS + PD group
MiRNA Control RS + PD P-value
miR-26a 0.916 (0.281-1.000) 0.521 (0.521-1.421) 0.343
miR-32 0.564 (0.343-0.926) 1.762* (0.980-3.168) 0.033
miR-127 7.550 (4.140-10.960) 8.260 (4.497-12.023) 0.806
miR-133b 0.757 (0.452-1.266) 1.054 (0.546-2.038) 0.468
miR-135a 2.963 (1.930-4.549) 4.375 (2.774-6.902) 0.285
miR-517 0.888 (0.617-1.207) 1.147 (0.749-1.630) 0.372
miR-640 0.429 (0.219-0.742) 0.402 (0.173-0.778) 0.902
miR-1287 1.059 (0.411-2.733) 1.560 (0.576-4.228) 0.598
Data are expressed as adjusted copies. Data are presented as least square means (LSMs) and 95% confidence intervals (CIs) are included in parentheses.
*P < 0.05 (ANOVA GLM).
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participant analysis stage, the means of the relative copies for each
treatment group were calculated and from this the fold-change was
estimated. The resulting data are summarized in Table 3. The direction
of fold-change were the same for seven out of eight miRNAs, the
exception being miR-133b, and we observed some differences in the
degree of change, for example the magnitude of fold-change in
miR-135a for individual participant data was half that observed in the
screening array (1.49 vs 3.19).
4 | DISCUSSION
miRNAs regulate the expression of thousands of genes by inhibiting
their expression and, consequently, have effects on many biological
processes including those involved in tumorigenesis.7,15,18 Abnormal
expression of miRNAs is implicated in the pathogenesis of CRC, where
it is associated with disease progression, treatment response, and
prognosis.19,20miRNAs have potential to be used as cancer biomarkers
since altered expression is observed not only in colorectal tissue but
also in the plasma, stool, and urine from CRC patients.11,12 However,
little is known about the potential of miRNAs as early markers of CRC
risk and how dietary factors may modulate these markers.
In the current study, we used a multi-step approach to identify
miRNAs in the colorectal mucosa of healthy individuals that are
potentially regulated by two NDCs (RS and PD). Using a whole
miRNome PCR array screen, we first compared the expression of 1008
miRNAs in pooled samples from rectal mucosal biopsies from
participants who were randomized to RS + PD or to Control for 50 d.
Theuseofpooling techniqueshasbeenappliedwidely in “omics” studies
including those analyzing miRNA expression21–23 and is particularly
valuable when samples are precious or limited.24 This screening stage
revealed 33 miRNAs that were up-regulated and 78 miRNAs that were
down-regulated by ≥2-fold in the RS + PD group compared with the
Control group. From these, eight miRNAs (miR-26a, miR-21, miR-133b,
miR-135a, miR-517, miR-640 andmiR-1287, andmiR-32) were selected
for validation in individual participant samples. Validation by qPCR
revealed consistent fold-change direction for seven of the eight
miRNAs. A possible explanation for the inconsistency observed for
miR-133b is the increasedchanceoferror associatedwith thePCRarray,
whereas qPCR analysis of individual participant samples provides a
more reliable and robust method with reduced chance of error,
especially as all analyses were performed in duplicate. Fold-changes
were lower in the qPCR data compared with the array data and we
expect that this resulted from differences in miRNA abundance in the
pooled samples, whichmay not have beenmathematically equivalent to
the mean of the abundances in individual participant samples.
Post-intervention, miR-32 expression was approximately three-
fold greater in participants supplementedwith RS + PD comparedwith
the Control (P = 0.033). At first sight, our findings are surprising asmiR-
32 expression has been found to be up-regulated in colon tumor tissue
compared with normal tissue and increased with advancing tumor
stage.25 miR-32 has been shown to promote proliferation, migration,
and invasion in colorectal and gastric cancer cells and reduces
apoptosis.17,26,27 There also appears to be a connection between
miR-32 and inflammation via the regulation of tumor necrosis factor
receptor-associated factor-3 (TRAF3), an activator of the non-
canonical NF-κB pathway.28 Therefore, downregulation of TRAF3
by miR-32 could lead to increased inflammation and effects on other
processes such as cell proliferation and cell death through stimulated
NF-κB signaling.29–31
While our findings are contradictory to evidence supporting
butyrate’s anti-inflammatory properties, it is possible that effects on
miR-32 expression and consequently on the NF-κB non-canonical
pathway could be one of the mechanisms via which NDCs modulate
processes such as cell proliferation and apoptosis.5 The very limited
research on the effects of NDCs on miRNA expression in the large
bowel mucosa suggests that RS and butyrate may reduce the
expression of oncogenic miRNAs.14,15 To our knowledge, our study
is the first to report the effects of NDC supplementation on miR-32
expression in the human colorectal epithelium. The observed
increase in miR-32 expression could be one of the mechanisms
through which, in healthy colorectal cells, butyrate stimulates cell
proliferation.32–34 In contrast, NDCs and butyrate reduce cell
proliferation and promote apoptosis in CRC cells,35–39 referred to
as the butyrate paradox,40 and the role of miRNAs in mediating
these phenomena in both healthy and cancer tissue deserves further
investigation.
TABLE 3 Comparison of fold-changes in miRNA expression between control and RS + PD samples using PCR array and subsequent qPCR
validation on individual participant samples
MiRNA Whole miRNome PCR array qPCR validation Same fold-change direction
miR-135a 3.19 1.49 (0.26) Yes
miR-517 2.40 1.73 (0.59) Yes
miR-26a 2.36 1.51 (0.32) Yes
miR-32 −1.91 −1.12 (0.31) Yes
miR-127 −3.24 −1.06 (0.17) Yes
miR-1287 −3.55 −1.05 (0.38) Yes
miR-640 −12.21 −1.12 (0.30) Yes
miR-133b −13.79 1.20 (0.44) No
Data are presented as fold-changes (RS + PD group compared with the control group) where data were normalized relative to RNU-6 and SNORD68. Data for
the qPCR validation were calculated using the mean of all individual samples. SEM are presented in parentheses.
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Although, we did not observe significant effects of NDCs on
expression of the additional seven miRNAs quantified, further
investigation of possible effects of NDCs and other dietary factors
on these miRNA in larger studies is warranted. We observed
considerable inter-individual variation in response to supplementation
(evidenced by relatively large SEM values—Table 3) so that despite
mean differences of up to 50%, these were not statistically significant.
Furthermore, some of these miRNAs may have potential for
development as biomarkers in investigations of the protective or
detrimental effects of dietary factors, such as red meat and dietary
fibre, on CRC risk. For example, miR-128741 and miR-51742 are
upregulated in CRC tissue andmiR-133b (which has been proposed to
be a tumor suppressor) is downregulated in SW-620 and HT-29 colon
cells.43 In addition, miR-135a has been identified as a biomarker of
CRC in serum44 and was downregulated by butyrate and trichostatin
A, another HDACi, in LT97 colon adenoma cells. This effect was
associated with reduced cell proliferation, suggesting that miR-135a
may be involved in butyrate-mediated inhibition of cell proliferation in
CRC cells.8
This study is the first to use a multi-step approach to identify
miRNAs in the colorectal mucosa of healthy individuals that are
regulated by RS and PD. Participants in the study had been shown at
endoscopy to have a normal colon and rectum and supplementation
using a randomized double-blind design ensured that observed effects
are likely to be causal. This study has shown that miR-32 expression in
the colorectal mucosa of healthy human participants increased
substantially after supplementation with RS + PD for 50 d. Given the
potential roles of this miRNA in regulation of the cell cycle,
inflammation, and interactions with the gut microbiota, further studies
are warranted to confirm our findings and to investigate the utility of
miR-32 as a diet-responsive biomarker of gut health. The findings from
this RCT study, although relatively small, provide valuable evidence of
causality which is free from confounding issues associated with
observational studies, such as the subjectivity of self-reported dietary
data.
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